Drug Profile


Alternative Names: AZD-9291; Mereletinib; TAGRISSO

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Eli Lilly; European Thoracic Oncology Platform; Incyte Corporation; Kyushu University; National Cancer Institute (USA); National University Hospital (Singapore); Singapore Clinical Research Institute
  • Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Carcinomatous meningitis
  • Phase I Solid tumours

Most Recent Events

  • 08 Aug 2017 AstraZeneca plans a phase II trial for Non-small cell lung cancer(Metastatic disease, Late-stage disease) (NCT03239340)
  • 11 Jul 2017 AstraZeneca completes AURA2 and AURA phase II trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease) in USA, Canada, Hong Kong, Italy, Japan, South Korea, Spain and Taiwan (AstraZeneca pipeline, July 2017)
  • 11 Jul 2017 AstraZeneca completes the phase III AURA3 trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA, Australia, Canada, Hong Kong, Italy, Taiwan, Sweden, Germany, Japan, South Korea, Spain, Russia, the Netherlands, China, France, Hungary, Mexico and United Kingdom (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top